-
Consistency evaluation of generic drugs is advancing!
Time of Update: 2022-09-06
On July 29, information from the State Food and Drug Administration showed that Huahai Pharmaceutical's 4 types of generic valsartan and hydrochlorothiazide tablets for the treatment of mild to moderate essential hypertension whose blood pressure cannot be adequately controlled by a single drug was approved .
-
Mergers and acquisitions have become an important part of the strategic layout of pharmaceutical equipment companies!
Time of Update: 2022-09-06
According to statistics, judging from the date of the first announcement and excluding transaction failure cases, as of August 23 this year, a total of 1,531 company mergers and acquisitions have occurred in the A-share market, an increase of 23.
-
In August, institutions gathered to investigate the pharmaceutical field, and the breakthrough strength of innovative technology transformation attracted much attention
Time of Update: 2022-09-06
If an investor asks, "Fujilay currently has a new enzymatic process improvement in technology, what are the advantages of the company's use of synthetic biology to produce lipoic acid?" In response to this question, Fujilay said that the company has carried out in-depth research and development with East China University of Science and Technology.
-
The CXO sector is strong again and is expected to rise in the long term!
Time of Update: 2022-09-06
As for the reasons for the changes in performance, the company explained that the decline in revenue and the sharp increase in net profit attributable to the parent were mainly due to the investment income generated by the company’s previous purchase of its subsidiary, Quantum Hi-Tech’s prebiotic business, and the equity transfer delivery was completed on June 9 this year .
-
Changsha pharmacies can also buy price-reduced drugs for centralized procurement!
Time of Update: 2022-09-06
Recently, the Zibo Medical Insurance Bureau has also launched the "national centralized purchase of drugs into pharmacies" service, with a map covering 656 of the city's pharmacies.
-
The sales revenue of the four major pharmacies in the first half of the year all exceeded 7 billion yuan, and the growth rate of net profit slowed down
Time of Update: 2022-09-06
Among them, the data shows that from the 2019 interim report to the 2022 interim report, Yifeng Pharmacy's net profit growth rate attributable to the parent company was 36.
-
The four major pharmaceutical business giants, the whole business in the first half of 2022
Time of Update: 2022-09-06
enterprises According to the data released by the four companies, in the medical device business in the first half of 2022, Sinopharm Holdings achieved an operating income of 53.
-
Semi-annual report observation: the development of leading pharmaceutical equipment companies is still accelerating in 2022
Time of Update: 2022-09-06
In the report, Chutian Technology suggested that in 2022, the proportion of vaccine-related equipment contribution may be reduced, resulting in the risk of equity incentive performance assessment not meeting expectations; and the company's 2022 annual new order target of 10 billion, due to the epidemic.
-
These 14 pharmaceutical companies achieved a net profit of more than 2 billion yuan
Time of Update: 2022-09-06
Regarding the substantial growth in performance, Mindray Medical stated that first, the company's main business continued to show a good development trend during the reporting period, and the product competitiveness continued to strengthen, and the mid-to-high-end sales of the product structure increased steadily; second, the company focused on the direction of strategic development planning, steadily Promoting various tasks in an orderly manner, actively exerting operational advantages in R&D, technology, procurement, manufacturing, quality, products, markets, channels, services, etc.
-
2022 China Pharmaceutical Industry Technology Annual Conference Schedule Update!
Time of Update: 2022-09-06
All relevant units: In order to implement the "14th Five-Year Plan" development plan of the national pharmaceutical industry, promote the innovation-driven transformation of the pharmaceutical industr
-
What are the basic conditions that drug online sales enterprises should have, and how to strengthen monitoring?
Time of Update: 2022-09-06
On September 1, the website of the State Food and Drug Administration released a policy interpretation on the Measures for the Supervision and Administration of Drug Online Sales. The specific interp
-
The inaugural meeting of the Pharmaceutical Excipients Professional Committee of the Chinese Pharmaceutical Association was held in Beijing
Time of Update: 2022-09-06
Group photo of the inaugural meeting of the Pharmaceutical Excipients Professional Committee of the Chinese Pharmaceutical Association Chairman Sun Xianze delivered a speech Chairman Sun Xianze issued a letter of appointment to the chairman and vice chairman On September 1, the inaugural meeting of the Pharmaceutical Excipients Professional Committee of the Chinese Pharmaceutical Association was held in Beijing.
-
The price cut is coming!
Time of Update: 2022-09-06
[Pharmaceutical Network Industry News] Recently, Shanxi Pharmaceutical Equipment Center issued a notice on the price reduction of some drugs, involving a total of 22 varieties from 19 companies, involving varieties with a unit price of more than 1,000 yuan, including doxorubicin hydrochloride liposome injection, ceti Distributing injections, etc.
-
With the continuous acceleration of the development of the biopharmaceutical industry, pharmaceutical machine companies are beginning to expand production
Time of Update: 2022-09-06
The development of the biopharmaceutical industry continues to accelerate (Source: Pharmaceutical Network) Pharmaceutical companies have expanded production, and biomedical equipment companies have ushered in good news.
The development of the biopharmaceutical industry continues to accelerate (Source: Pharmaceutical Network) Pharmaceutical companies have expanded production, and biomedical equipment companies have ushered in good news.
-
Keji Pharmaceutical's US CGMP production plant completed the first clinical batch production of CAR-T products
Time of Update: 2022-09-06
Exterior view of Keji Pharmaceutical's CGMP production plant The RTP GMP production facility, with a total construction area of approximately 3,300 square meters, will provide Keji Pharmaceuticals with additional capacity to produce autologous CAR-T cell products for 700 patients per year to support clinical research and early commercial use in North America and Europe change .
-
How do R&D biopharmaceutical companies cope with the challenge of tight cash flow?
Time of Update: 2022-09-06
Unlisted companies: Priority will be given to key projects For unlisted biomedical R&D companies, facing the unfavorable environment of capital winter, declining valuation and financing difficulties, it is first necessary to study and analyze the company's financial situation and project funding needs, and must control expenses and cash flow, and do not arbitrarily expand expenditures.
-
Pfizer and other three major new crown vaccine companies in court!
Time of Update: 2022-09-06
East Sunshine Patent Infringement Wins Recently, the State Intellectual Property Office (SIPO) made a ruling in accordance with the Administrative Adjudication Measures for Major Patent Infringement Disputes that the patent of the innovative drug Ou Tangning ® (Ligliliptin Tablets) independently developed by Boehringer Ingelheim was infringed by Guangdong Dongguang Pharmaceutical Co.
-
Policies have been introduced intensively, and a large number of pharmaceutical companies have vigorously focused on innovative traditional Chinese medicine drugs
Time of Update: 2022-09-06
Among them, Fangsheng Pharmaceutical stated in this year's semi-annual report that it is committed to building a health industry group with innovative traditional Chinese medicine as its core, and driving the continuous improvement of the company's core competitiveness with "innovative traditional Chinese medicine research and development" and "management reform" .
-
Hengrui and Heyi won the first imitation of ophthalmic drugs, and 7 exclusive evaluation varieties are eye-catching!
Time of Update: 2022-09-06
0 China Drug Review DatabaseSince the beginning of this year, 5 ophthalmic drugs (15 product specifications) have been approved, and the diquaphososoline sodium eye drops of Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Pharmaceutical, and the lidocaine hydrochloride eye gel of Sichuan Heyi Pharmaceutical are the first in China.
-
The high-level turnover of pharmaceutical companies is frequent, and changes under the medical reform may continue
Time of Update: 2022-09-06
[Pharmaceutical Network Industry News] Recently, AstraZeneca announced that it has appointed Liu Ming as Vice President of AstraZeneca China, Head of the Lung Cancer Treatment and Tumor Immunotherapy-related Business Units of the Oncology Division, and joined the Chinese management team to directly report to AstraZeneca.
